Videos

Adherence With CDK 4/6 Inhibitors

December 12th 2018

Patient Management of CDK 4/6 Inhibitors

December 12th 2018

Dispensing of CDK4/6 Inhibitors

December 12th 2018

Multidisciplinary Approach: Managing CDK4/6 Inhibitors

December 12th 2018

Patients' Perspectives on CDK4/6 Inhibitors

December 12th 2018

Benefits and Challenges of CDK4/6 Inhibitors

December 12th 2018

Metastatic Breast Cancer: CDK4/6 Inhibitors

December 12th 2018

Improving Care for Patients With Metastatic Breast Cancer

December 12th 2018

Educating Patients and Staff on Using CDK4/6 Inhibitors

December 12th 2018

Best Practices for Managing Patients on CDK4/6 Inhibitors

December 12th 2018

Multidisciplinary Care in Breast Cancer

December 12th 2018

Considerations for Treating Patients with CDK4/6 Inhibitors

December 12th 2018

CDK4/6 Inhibitors in Metastatic Breast Cancer

December 12th 2018

Medically Integrated Pharmacy Teams Spur Innovations

December 12th 2018

Oral Oncolytics and Patient Adherence

December 12th 2018

Medically Integrated Dispensing Service Best Practices

December 12th 2018

Practical Challenges in Switching to CDK4/6 Inhibitors

December 12th 2018

The Efficacy and Safety of CDK4/6 Inhibitors

December 12th 2018

Roles of the Oncologist Versus Pharmacist

December 12th 2018

Multidisciplinary Approach to Managing Oral Oncolytics

December 12th 2018

The Advent of Oral Oncolytics and Patient Access

December 12th 2018

Vertical Integration and Looking Toward the Future

December 11th 2018

Impact of Competition on Pricing in the Future

December 11th 2018

Factors Determining Inclusion of Biosimilars on the Formulary

December 11th 2018

Educating the Patient and Providers on Biosimilars

December 11th 2018

Role of Specialty Pharmacy Regarding Biosimilars

December 11th 2018

Challenges for Payers With Costs of Biosimilars

December 11th 2018

Pricing of Biosimilars With Biologics and Other Biosimilars

December 11th 2018

Regulatory and Legislative Impact on Biosimilars

December 11th 2018

Progress of Biosimilars and Personal Experience

December 11th 2018

Videos

Adherence With CDK 4/6 Inhibitors

Patient Management of CDK 4/6 Inhibitors

Dispensing of CDK4/6 Inhibitors

Multidisciplinary Approach: Managing CDK4/6 Inhibitors

Patients' Perspectives on CDK4/6 Inhibitors

Benefits and Challenges of CDK4/6 Inhibitors

Metastatic Breast Cancer: CDK4/6 Inhibitors

Improving Care for Patients With Metastatic Breast Cancer

Educating Patients and Staff on Using CDK4/6 Inhibitors

Best Practices for Managing Patients on CDK4/6 Inhibitors

Multidisciplinary Care in Breast Cancer

Considerations for Treating Patients with CDK4/6 Inhibitors

CDK4/6 Inhibitors in Metastatic Breast Cancer

Medically Integrated Pharmacy Teams Spur Innovations

Oral Oncolytics and Patient Adherence

Medically Integrated Dispensing Service Best Practices

Practical Challenges in Switching to CDK4/6 Inhibitors

The Efficacy and Safety of CDK4/6 Inhibitors

Roles of the Oncologist Versus Pharmacist

Multidisciplinary Approach to Managing Oral Oncolytics

The Advent of Oral Oncolytics and Patient Access

Vertical Integration and Looking Toward the Future

Impact of Competition on Pricing in the Future

Factors Determining Inclusion of Biosimilars on the Formulary

Educating the Patient and Providers on Biosimilars

Role of Specialty Pharmacy Regarding Biosimilars

Challenges for Payers With Costs of Biosimilars

Pricing of Biosimilars With Biologics and Other Biosimilars

Regulatory and Legislative Impact on Biosimilars

Progress of Biosimilars and Personal Experience

Trending on Pharmacy Times

FDA Approves Nerandomilast for Progressive Pulmonary Fibrosis

OTC Case Studies: Supplements for Aging

Redefining Roles: Technicians Reduce Oncology Drug Waste in Specialty Pharmacy

Early RSV Vaccine Uptake Among Older Adults Reveals Significant Access Gaps

Debunking Pharma Stigma: How Industry Partnerships Benefit Clinical Oncology Pharmacists